Journal of gastrointestinal and liver diseases : JGLD最新文献

{"title":"Acute extensive portal vein system thrombosis in a patient with acute pancreatitis secondary to pancreatic cancer.","authors":"Junxiu Chen, Liyan Dong, Shengye Yang, Ran Wang, Xingshun Qi","doi":"10.15403/jgld-6722","DOIUrl":"https://doi.org/10.15403/jgld-6722","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"494-496"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maltese Cross in Erythropoietic Protoporphyria.","authors":"Ryuichi Wada, Kenji Matsuda, Tomoko Hirai","doi":"10.15403/jgld-6831","DOIUrl":"https://doi.org/10.15403/jgld-6831","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"328"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Metabolic and Inflammatory Changes Associated with Helicobacter Pylori Eradication: A Controlled Before-after Cohort Comparing Eradication Success and Persistent Infection.","authors":"Ali Zeynettin, Selin Ozdemir, Sibel Bilgili, Gamze Altan","doi":"10.15403/jgld-6879","DOIUrl":"https://doi.org/10.15403/jgld-6879","url":null,"abstract":"<p><strong>Background and aims: </strong>Helicobacter pylori (H. pylori) infection has been linked to systemic metabolic and inflammatory disturbances beyond the gastric mucosa, yet evidence regarding biomarker changes after eradication remains heterogeneous. This study evaluated systemic metabolic and inflammatory changes associated with eradication success versus persistent infection, using H. pylori-negative controls within a controlled before-after cohort framework.</p><p><strong>Methods: </strong>Adults undergoing stool H. pylori antigen testing at a tertiary referral center in Türkiye (2020-2025) with paired baseline (pre) and follow-up (post) laboratory measurements were included. Participants were classified as H. pylori-negative controls, eradication success (baseline positive, follow-up negative), or eradication failure (baseline and follow-up positive). Co-primary endpoints were follow-up HOMA-IR and hsCRP (log-transformed), compared between groups using ANCOVA adjusted for baseline values and prespecified covariates. Prespecified supportive analyses used a difference-in-differences framework. Secondary outcomes included glycemic measures, lipid profile, hematological inflammation indices, and liver-related biomarkers; TyG index and FIB-4 were assessed exploratorily.</p><p><strong>Results: </strong>A total of 3,756 individuals were included (1,321 controls; 1,847 eradication success; 588 eradication failure). In adjusted analyses, eradication success showed a more favorable follow-up profile with lower insulin resistance and systemic inflammation compared with controls, whereas eradication failure showed an opposing pattern. Directionally consistent differences were also observed across secondary metabolic, inflammatory, and hepatic biomarkers and were supported by difference-in-differences analyses.</p><p><strong>Conclusions: </strong>Compared with H. pylori-negative controls, eradication success was associated with a more favorable systemic short-term metabolic-inflammatory profile, whereas persistent infection tended to show the opposite pattern. Prospective studies with longer follow-up are needed to determine durability and clinical relevance.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"335-343"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Chiara Valentina Luglio, Agostino Di Ciaula, Silvia Sozzi, Claudia Conforti, Gianluca Bitonto, Piero Portincasa","doi":"10.15403/jgld-7570","DOIUrl":"https://doi.org/10.15403/jgld-7570","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"493"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-Generation Probiotics in Obesity: From Microbial Signatures to Therapeutic Reality.","authors":"Giuseppe Guido Maria Scarlata, Ludovico Abenavoli","doi":"10.15403/jgld-7232","DOIUrl":"https://doi.org/10.15403/jgld-7232","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"314-317"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"Ilaria Milani, Daniele Napolitano, Monica Petralito, Stefano Romano Capatti, Elena Gennari, Simone Amato, Viviana Di Cosimo, Giulia Petruccini, Nicoletta Orgiana, Mattia Bozzetti, Alessio Lo Cascio, Rosario Caruso","doi":"10.15403/jgld-7296","DOIUrl":"10.15403/jgld-7296","url":null,"abstract":"<p><p>Erratum for: Promoting Self-Care in Individuals with Inflammatory Bowel Disease: A Scoping Review J Gastrointestin Liver Dis. 2026;35:100-108 PMID: 41894726 DOI: 10.15403/jgld-6438.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"503-504"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Persimmon Phytobezoar in the Stomach.","authors":"Zhiming Liu, Deqiang Zhang","doi":"10.15403/jgld-6732","DOIUrl":"https://doi.org/10.15403/jgld-6732","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"323"},"PeriodicalIF":2.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden and Impact of Infections in Acute Pancreatitis: Insights from the National Inpatient Sample.","authors":"Isha Kohli, Anmol Singh, Mehul Solanki, Saniya Jiwani, Carol Singh, Vikash Kumar, Aalam Sohal, Dalbir Sandhu","doi":"10.15403/jgld-6842","DOIUrl":"https://doi.org/10.15403/jgld-6842","url":null,"abstract":"<p><strong>Background and aims: </strong>Acute pancreatitis (AP) is an inflammatory disease with a wide range of severity. Disruption of the intestinal barrier and translocation of gut flora increase the risk of infectious complications. Our study evaluates the impact of infections on in-hospital outcomes among admitted AP patients.</p><p><strong>Methods: </strong>Hospitalized adult AP patients were identified from the National Inpatient Sample (NIS) database (2016-2022) using ICD-10 codes. Patients with missing demographic or mortality data were excluded, and those remaining were stratified by infection type. Demographics, AP etiology, comorbidities, and clinical outcomes were analyzed. The primary outcome was in-hospital mortality by infection type. Secondary outcomes included sepsis, shock, acute kidney injury (AKI), intensive care unit (ICU) admission, deep vein thrombosis (DVT), pulmonary embolism (PE), and portal vein thrombosis (PVT).</p><p><strong>Results: </strong>Among 2,467,233 patients with AP, 392,255 (15.9%) developed infectious complications. Urinary tract infections (UTIs) were most common (51%), followed by pneumonia (29.7%), cholangitis (14.5%), Clostridioides difficile infection (CDI) (7.9%), cellulitis (5.6%), and spontaneous bacterial peritonitis (SBP) (1.9%). SBP had the highest mortality (21.1%), followed by pneumonia (12.8%), whereas mortality was lower with UTI (4.5%), cholangitis (5.2%), CDI (6.9%), and cellulitis (5.9%). AP patients with infections had higher in-hospital mortality after adjusting for confounding factors (6.7% vs 1.6%, p < 0.001).</p><p><strong>Conclusions: </strong>Infectious complications, particularly SBP and pneumonia, were associated with significantly worse in-hospital outcomes in patients with AP, highlighting the importance of early recognition and management.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148858024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Arteriovenous Malformation with Acute Pancreatitis-Induced Aneurysm.","authors":"Shu Yoshihara, Kazuyo Yoshihara, Shioto Suzuki, Taku Yaegashi, Yoshihisa Ookawa","doi":"10.15403/jgld-6935","DOIUrl":"https://doi.org/10.15403/jgld-6935","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148858034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Risk Factors of Developing Liver Steatosis among Patients with Chronic Hepatitis B: A National Cohort from Romania.","authors":"Anca Trifan, Robert Nastasa, Carol Stanciu, Ermina Stratina, Tudor Cuciureanu, Cristina Maria Muzica, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Ana-Maria Singeap, Irina Girleanu, Laura Huiban, Speranta Iacob, Corina Silvia Pop, Mihaela Moscalu, Liana Gheorghe","doi":"10.15403/jgld-7192","DOIUrl":"10.15403/jgld-7192","url":null,"abstract":"<p><strong>Background and aims: </strong>The coexistence of liver steatosis in patients with chronic viral hepatitis B (CHB) is growing relevant as the global epidemic of obesity and type 2 diabetes mellitus (T2DM). The aim of this study was to identify the metabolic risk factors linked to steatotic liver disease (SLD) in Romanian patients with CHB.</p><p><strong>Methods: </strong>In this prospective study, we evaluated 320,000 individuals in the LIVE(RO)2 nationwide screening program in Romania from 2021 to 2023. The majority of the patients had undergone transient elastography using controlled attenuation parameter (CAP) to diagnose liver steatosis, and they belonged to vulnerable categories. Exclusion criteria included heavy alcohol consumption, any other liver disease unrelated to CHB, and the lack of CAP evaluation.</p><p><strong>Results: </strong>5,321 individuals (1.67%) were found with CHB in the screening program. In the final analysis we included 1,970 patients, with a mean age of 55.87±13.84 years; 57.9% of them were males, with a mean body mass index (BMI) level of 27.26 kg/m², and 61.9% of the patients were vulnerable. The prevalence of SLD was 42.2% in the group of vulnerable individuals, compared with non-vulnerable participants, who had a prevalence of SLD of 26.4%. Moreover, patients with vulnerable conditions have a higher prevalence of T2DM (11.5%), hypertension (41.3%), and raised BMI levels ≥25 kg/m² (71.3%). In our study, vulnerable subjects had a higher prevalence of hepatitis B virus e antigen (HBeAg) positivity of 3%, and it was found to be a protective risk factor for hepatic steatosis development (aOR=0.397). Also, these patients had a higher prevalence of severe liver fibrosis (≥ F3) of 17.1%, compared with those non-vulnerable, with a prevalence of 9.7% of severe liver fibrosis. More than that, we find that the presence of HBeAg-positive increases the risk of severe liver fibrosis progression 6 times higher.</p><p><strong>Conclusions: </strong>In our study we found a prevalence of hepatic steatosis of 42.2% in the cohort of vulnerable untreated patients with CHB, and the prevalence of severe fibrosis was 17.1%. Presence of HBeAg-positive was found to be a protective risk factor for hepatic steatosis but accelerates the development of severe fibrosis along with T2DM, which is more common in the vulnerable CHB cohort.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":" ","pages":"377-383"},"PeriodicalIF":2.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148858019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}